Santos García, DiegoMartínez Castrillo, Juan CarlosPuente Périz, VíctorSeoane Urgorri, AgustínFernández Díez, ServandoBenita León, VicenteUdaeta Baldivieso, BeatrizCampolongo, AntoniaMariscal Pérez, NatividadUniversitat Oberta de Catalunya (UOC)2019-10-222019-10-222016-06-01Santos García, D., Martínez Castrillo, J.C., Puente, V., Seoane Urgorri, A., Fernández Díez, S., Benita León, V., Udaeta Baldivieso, B., Campolongo, A. & Mariscal Pérez, N. (2016). Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa. Neurodegenerative disease management, 6(3), 187-202. doi: 10.2217/nmt-2016-00111758-20241758-2032https://hdl.handle.net/10609/101912Patients with Parkinson's disease often have a good initial response to dopaminergic therapy but later usually develop motor fluctuations and dyskinesia. In these patients, continuous infusion of levodopa-carbidopa intestinal gel (LCIG) allows for maintaining adequate dopamine levels and for improving motor and nonmotor symptoms, as well as quality of life and autonomy. Adequate candidate selection and follow-up are crucial for treatment success. Management should be multidisciplinary, and patient and caregiver education is a priority. This expert consensus document has been developed by a team of neurologists, gastroenterologists and nurses who have a vast experience in LCIG therapy, with an intention to provide knowledge and tools to facilitate patient management throughout all phases of LCIG treatment process.engcc-by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Advanced Parkinson's diseaseClinical guidelinesDyskinesiaLevodopa-carbidopa intestinal gelMotor fluctuationSpercutaneous endoscopic gastrostomyParkinson's diseaseinfo:eu-repo/semantics/articleParkinson, Malaltia deParkinson, Enfermedad deinfo:eu-repo/semantics/openAccess10.2217/nmt-2016-0011